WO2011142461A1 - Anticorps pour le diagnostic de la sclérose latérale amyotrophique (sla) - Google Patents

Anticorps pour le diagnostic de la sclérose latérale amyotrophique (sla) Download PDF

Info

Publication number
WO2011142461A1
WO2011142461A1 PCT/JP2011/061069 JP2011061069W WO2011142461A1 WO 2011142461 A1 WO2011142461 A1 WO 2011142461A1 JP 2011061069 W JP2011061069 W JP 2011061069W WO 2011142461 A1 WO2011142461 A1 WO 2011142461A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
seq
acid sequence
sod1
mutated
Prior art date
Application number
PCT/JP2011/061069
Other languages
English (en)
Japanese (ja)
Inventor
秀憲 一條
英起 西頭
Original Assignee
国立大学法人 東京大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立大学法人 東京大学 filed Critical 国立大学法人 東京大学
Priority to JP2012514849A priority Critical patent/JP5828521B2/ja
Publication of WO2011142461A1 publication Critical patent/WO2011142461A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90283—Oxidoreductases (1.) acting on superoxide radicals as acceptor (1.15)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Les problèmes abordés par la présente invention sont la détermination d'une partie du mécanisme moléculaire derrière la pathogenèse de la sclérose latérale amyotrophique (SLA) et l'utilisation dudit mécanisme moléculaire pour rechercher des risques de SLA. Lesdits problèmes sont abordés par la fourniture d'une méthode de détection des risques de SLA par la détection d'une protéine SOD1 mutante. A savoir, lesdits problèmes sont abordés par la fourniture d'un anticorps pour la détection d'une protéine SOD1 mutante, ledit anticorps se liant à la protéine SOD1 mutante mais pas à la protéine SOD1 de type sauvage (c'est-à-dire normale).
PCT/JP2011/061069 2010-05-13 2011-05-13 Anticorps pour le diagnostic de la sclérose latérale amyotrophique (sla) WO2011142461A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012514849A JP5828521B2 (ja) 2010-05-13 2011-05-13 筋萎縮性側索硬化症（ａｌｓ）の診断のための抗体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010-111375 2010-05-13
JP2010111375 2010-05-13

Publications (1)

Publication Number Publication Date
WO2011142461A1 true WO2011142461A1 (fr) 2011-11-17

Family

ID=44914512

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2011/061069 WO2011142461A1 (fr) 2010-05-13 2011-05-13 Anticorps pour le diagnostic de la sclérose latérale amyotrophique (sla)

Country Status (2)

Country Link
JP (1) JP5828521B2 (fr)
WO (1) WO2011142461A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10689394B2 (en) 2016-06-14 2020-06-23 The University Of Tokyo Thieno[2,3-b]pyridine derivative, quinoline derivative, and use thereof
WO2023033049A1 (fr) * 2021-09-02 2023-03-09 国立大学法人滋賀医科大学 Anticorps et fragment d'anticorps ayant des propriétés de liaison à la protéine sod1 mutante provoquant la sclérose latérale amyotrophique

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007025385A1 (fr) * 2005-08-31 2007-03-08 Universite Laval Anticorps et leur utilisation dans le traitement, la prevention et le diagnostic d'une maladie associee a des anomalies de sod1
WO2009100141A1 (fr) * 2008-02-04 2009-08-13 The Curators Of The University Of Missouri Prédiction et diagnostic de la myélopathie dégénérative canine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007025385A1 (fr) * 2005-08-31 2007-03-08 Universite Laval Anticorps et leur utilisation dans le traitement, la prevention et le diagnostic d'une maladie associee a des anomalies de sod1
WO2009100141A1 (fr) * 2008-02-04 2009-08-13 The Curators Of The University Of Missouri Prédiction et diagnostic de la myélopathie dégénérative canine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MAKOTO URUSHITANI: "ALS ni Taisuru Vaccine Kotai Ryoho no Tenbo", NANBYO TO ZAITAKU CARE, vol. 15, September 2009 (2009-09-01), pages 35 - 39 *
MAKOTO URUSHITANI: "Molecular targeting by immunotherapy in ALS", IGAKU NO AYUMI, vol. 235, 16 October 2010 (2010-10-16), pages 255 - 260 *
URUSHITANI MAKOTO. ET AL.: "Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis", PNAS, vol. 104, 2007, pages 2495 - 2500, XP002508784, DOI: doi:10.1073/PNAS.0606201104 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10689394B2 (en) 2016-06-14 2020-06-23 The University Of Tokyo Thieno[2,3-b]pyridine derivative, quinoline derivative, and use thereof
WO2023033049A1 (fr) * 2021-09-02 2023-03-09 国立大学法人滋賀医科大学 Anticorps et fragment d'anticorps ayant des propriétés de liaison à la protéine sod1 mutante provoquant la sclérose latérale amyotrophique

Also Published As

Publication number Publication date
JP5828521B2 (ja) 2015-12-09
JPWO2011142461A1 (ja) 2013-07-22

Similar Documents

Publication Publication Date Title
CN108738323B (zh) 抗trem2抗体及其使用方法
AU2018274932B2 (en) Cancer cell-specific antibody, anticancer drug and cancer testing method
JP2022081543A (ja) 抗ｔｒｅｍ２抗体及びその使用方法
US9272022B2 (en) Compositions and methods for treating cancer and modulating stress granule formation
CN102369436B (zh) 用于检测jc多瘤病毒的方法
CN109563169A (zh) 抗hla-g特异性抗体
CN101820910B (zh) 结合细胞内prl-1多肽或prl-3多肽的抗体
EP2011513B1 (fr) Agents thérapeutiques employés dans le cadre de la maladie d'alzheimer et du cancer
UA128035C2 (uk) Антитіло, що специфічно зв'язує pd-1, і спосіб його застосування
DK2443149T3 (en) BACE1 inhibitory ANTIBODIES
CN101778867A (zh) 用于治疗胰腺肿瘤的组合物和方法
CN103282374A (zh) 用于治疗神经变性病症和阿尔茨海默病并改善正常记忆的方法和组合物
KR20160119806A (ko) 신규한 온전한 범위의 항-뎅기 항체
JP2018139530A (ja) 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
CN113906050B (zh) 抗EphA4抗体
CN110088131A (zh) 抗chikv抗体及其用途
CN112119091A (zh) 抗序列相似家族19成员a5的抗体及其使用方法
JP5828521B2 (ja) 筋萎縮性側索硬化症（ａｌｓ）の診断のための抗体
CN107921084A (zh) 含有活动精子结构域的蛋白质2和炎症
WO2021142963A1 (fr) Combinaison d'antigènes protéiques pour la détection d'auto-anticorps de la maladie d'alzheimer et application d'une combinaison d'antigènes protéiques
JP2022036962A (ja) 抗ｎｉｎｊ－１抗体及びその使用
CN115443150A (zh) 新型ddr1抗体和其用途
US10774143B1 (en) Modulation of T cell signaling via slat association with IP3R1
WO2016139941A1 (fr) Anticorps, fragment, molécule et agent de traitement anti-vhc
WO2022138707A1 (fr) Composition pharmaceutique pour le traitement de la sclérose latérale amyotrophique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11780717

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2012514849

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11780717

Country of ref document: EP

Kind code of ref document: A1